Insider trading

Period: 120 months Stock: NVCR + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

519 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

519 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

519 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

519 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
519 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
519 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

519 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
2 Nov 2024
Paravasthu Mukund Chief Operating Officer
Sold at will
$734.18 44 at 16.69
1.3%
Not planned
1 Nov 2024
Leonard Frank X EVP, Pres., Novocure Oncology
Sold at will
$9.53K 598 at 15.94
0.4%
Not planned
1 Nov 2024
Paravasthu Mukund Chief Operating Officer
Sold at will
$2.54K 160 at 15.88
4.4%
Not planned
31 Oct 2024
Puri Michal Nath Chief Human Resources Officer
Sold at will
$12.79K 810 at 15.79
0.7%
Not planned
2 Aug 2024
Cordova Ashley Chief Financial Officer
Sold at will
$13.86K 688 at 20.14
0.3%
Not planned
4 Jun 2024
VERNON W ANTHONY Director
Sold at will
$23.03K 964 at 23.89
0.6%
Not planned
4 Jun 2024
Sold at will
$23.03K 964 at 23.89
24.5%
Not planned
4 Jun 2024
LEUNG GABRIEL Director
Sold at will
$23.03K 964 at 23.89
1.2%
Not planned
4 Mar 2024
GROENHUYSEN WILHELMUS CM Chief Operating Officer
Sold at will
$19.48K 1,217 at 16.01
0.5%
Not planned
4 Mar 2024
Leonard Frank X EVP, Pres., Novocure Oncology
Sold at will
$13.45K 840 at 16.01
0.5%
Not planned
1 Mar 2024
GROENHUYSEN WILHELMUS CM Chief Operating Officer
Sold at will
$33.77K 2,107 at 16.03
0.8%
Not planned
1 Mar 2024
Leonard Frank X EVP, Pres., Novocure Oncology
Sold at will
$26.91K 1,679 at 16.03
1.0%
Not planned
28 Feb 2024
GROENHUYSEN WILHELMUS CM Chief Operating Officer
Sold at will
$37.18K 2,303 at 16.14
0.9%
Not planned
28 Feb 2024
Leonard Frank X EVP, Pres., Novocure Oncology
Sold at will
$33.54K 2,078 at 16.14
1.3%
Not planned
7 Nov 2023
Shah Pritesh Chief Growth Officer
Sold at will
$4.83K 382 at 12.65
0.3%
Not planned
1 Sep 2023
Cordova Ashley Chief Financial Officer
Sold at will
$19.26K 883 at 21.82
0.9%
Not planned
1 Sep 2023
GROENHUYSEN WILHELMUS CM Chief Operating Officer
Sold at will
$6.41K 294 at 21.82
0.1%
Not planned
1 Sep 2023
Shah Pritesh Chief Growth Officer
Sold at will
$5.96K 273 at 21.82
0.2%
Not planned
2 Aug 2023
Cordova Ashley Chief Financial Officer
Sold at will
$34.61K 1,144 at 30.25
1.1%
Not planned
7 Mar 2023
Leonard Frank X President, CNS Cancers US
Sold, plan not stated 2×
$625.21K 8,318 at 75.16
13.3%
3 Mar 2023
GROENHUYSEN WILHELMUS CM Chief Operating Officer
Sold, plan not stated 3×
$1.95M 25,635 at 76.16
10.9%
3 Mar 2023
Shah Pritesh Chief Growth Officer
Sold, plan not stated 3×
$1.63M 21,421 at 76.16
14.6%
3 Mar 2023
Leonard Frank X President, CNS Cancers US
Sold, plan not stated 3×
$562.82K 7,350 at 76.57
10.5%
3 Mar 2023
Cordova Ashley Chief Financial Officer
Sold, plan not stated 2×
$419.26K 5,505 at 76.16
5.2%
3 Mar 2023
Burke William Patrick Chief Human Resources Officer
Sold, plan not stated
$45.16K 593 at 76.16
0.9%
2 Mar 2023
Leonard Frank X President, CNS Cancers US
Sold, plan not stated 3×
$373.11K 4,951 at 75.36
7.8%
2 Mar 2023
GROENHUYSEN WILHELMUS CM Chief Operating Officer
Sold, plan not stated
$91.31K 1,213 at 75.28
0.7%
2 Mar 2023
Cordova Ashley Chief Financial Officer
Sold, plan not stated
$79.42K 1,055 at 75.28
1.1%
2 Mar 2023
Shah Pritesh Chief Growth Officer
Sold, plan not stated
$70.54K 937 at 75.28
0.9%
2 Mar 2023
Burke William Patrick Chief Human Resources Officer
Sold, plan not stated
$21.15K 281 at 75.28
0.4%
1 Mar 2023
Cordova Ashley Chief Financial Officer
Sold, plan not stated
$167.84K 2,198 at 76.36
2.2%
1 Mar 2023
GROENHUYSEN WILHELMUS CM Chief Operating Officer
Sold, plan not stated
$165.25K 2,164 at 76.36
1.2%
1 Mar 2023
Shah Pritesh Chief Growth Officer
Sold, plan not stated
$146.84K 1,923 at 76.36
1.9%
1 Mar 2023
Leonard Frank X President, CNS Cancers US
Sold, plan not stated
$128.59K 1,684 at 76.36
2.6%
1 Mar 2023
Burke William Patrick Chief Human Resources Officer
Sold, plan not stated
$57.65K 755 at 76.36
1.1%
5 Jan 2023
Danziger Asaf Chief Executive Officer
Sold, plan not stated 10×
$23.11M 212,500 at 108.74
94.0%
Sold half or more
5 Jan 2023
Leonard Frank X President, CNS Cancers US
Sold, plan not stated 9×
$4.43M 39,507 at 112.25
46.1%
5 Jan 2023
Weinberg Uri Chief Science Officer
Sold, plan not stated 4×
$945.76K 8,143 at 116.14
15.8%
5 Jan 2023
Shah Pritesh Chief Commercial Officer
Sold, plan not stated
$41.80K 387 at 108.00
0.5%
13 Oct 2022
Leonard Frank X President, CNS Cancers US
Sold, plan not stated
$513.37K 6,754 at 76.01
13.4%
6 Oct 2022
Leonard Frank X President, CNS Cancers US
Sold, plan not stated
$569.83K 6,754 at 84.37
11.8%
29 Sep 2022
Leonard Frank X President, CNS Cancers US
Sold, plan not stated
$522.42K 6,754 at 77.35
10.6%
22 Sep 2022
Leonard Frank X President, CNS Cancers US
Sold, plan not stated
$520.06K 6,754 at 77.00
9.6%
15 Sep 2022
Leonard Frank X Chief Development Officer
Sold, plan not stated 2×
$1.09M 12,271 at 88.52
14.8%
9 Sep 2022
Leonard Frank X Chief Development Officer
Sold, plan not stated
$163.94K 1,863 at 88.00
2.2%
6 Sep 2022
Leonard Frank X Chief Development Officer
Sold, plan not stated
$108.74K 1,384 at 78.57
1.6%
2 Sep 2022
Cordova Ashley Chief Financial Officer
Sold, plan not stated
$69.95K 885 at 79.04
1.2%
2 Sep 2022
Burke William Patrick Chief Human Resources Officer
Sold, plan not stated
$56.75K 718 at 79.04
1.3%
2 Sep 2022
Leonard Frank X Chief Development Officer
Sold, plan not stated
$46.16K 584 at 79.04
0.7%
2 Sep 2022
GROENHUYSEN WILHELMUS CM Chief Operating Officer
Sold, plan not stated
$23.39K 296 at 79.04
0.2%
Showing 51–100 of 519. ← Newer Page 2 of 11 Older →